<DOC>
	<DOCNO>NCT00760708</DOCNO>
	<brief_summary>Persantine drug routinely use determine blood flow heart diagnosis coronary heart disease . Persantine cause increase adenosine level blood . Adenosine naturally occur substance body increase blood flow . Adenosine normally remove bloodstream adenosine transporter , protein take adenosine blood cell . The increase adenosine level blood variable , cause variability unknown . A mutation transporter gene may contribute variability , may alter function . Thus , purpose study determine relationship mutation transporter function .</brief_summary>
	<brief_title>Circulating Adenosine Levels Before After Intravenous ( IV ) Persantine</brief_title>
	<detailed_description>Objectives : The overall goal proposal develop method achieve heart vascular protection ischemia thus improve soldier 's performance adverse environment . The major hypothesis new approach method develop enhance resistance stress-induced circulatory insufficiency myocardial ischemia . The goal determine whether decreased adenosine transporter function associate reduced physiological responsiveness vasculo-protective drug persantine use two vitro endpoint : ability persantine 1 ) inhibit platelet aggregation 2 ) inhibit [ 3H ] uridine uptake . Both endpoint indicate physiological responsiveness . Both relate directly cardiovascular protective effect , , persantine availability extracellular adenosine level anti-platelet property . Specifically , relationship circulate adenosine increase persantine vivo blockade radio-labeled uridine uptake erythrocyte platelet aggregation drug vitro determine . These investigation recruit subject undergoing persantine stress test Nuclear Cardiology Laboratory . Scientific Background Significance : Development method protect skeletal cardiovascular insufficiency main objective current research . Adenosine potent cyto-protective hormone release ischemia . The goal clinical research project test presence genetic polymorphism adenosine transporter gene determine whether associate altered persantine responsiveness . The hypothesis polymorphism associate decreased responsiveness persantine increase dose persantine overcome relative non-response . Specific Evaluations : -Persantine Administration : Persantine administer baseline evaluation intravenous dose ( 0.56 mg/kg ) 5 minute . -Adenosine level : Adenosine level measure baseline , 2 minute persantine dose . We recently modify adapt method measure nanomolar concentration adenosine human blood . -Adenosine transporter function : The transporter function determine ability persantine inhibit erythrocyte uptake radio-labeled uridine vitro . - Anti-platelet effect persantine : The platelet aggregation response persantine determine via whole blood aggregometry vitro ex vivo platelet response drug quantify . Preliminary Studies : Preliminary data show two non-synonymous single nucleotide polymorphism occur frequency 3-4 % exist persantine-binding region adenosine transporter gene . The goal present study determine functional significance polymorphism test association polymorphism ability persantine inhibit uridine ( uridine us transporter ) uptake platelet aggregation . These represent vitro functional endpoint subject polymorphism . The investigator also study association polymorphism clinical characteristic incidence MI , acute coronary syndrome , coronary bypass stenting procedure . Since NOT interventional study , consider clinical outcome endpoints traditional sense intervention carry . These consider clinical characteristic phenotype associate genotype polymorphism . Primary secondary outcome endpoint : The goal present study determine functional significance polymorphism test association polymorphism ability persantine inhibit uridine ( uridine us transporter ) uptake platelet aggregation . These represent vitro functional endpoint subject polymorphism . The investigator also study association polymorphism clinical characteristic incidence MI , acute coronary syndrome , coronary bypass stenting procedure . Since NOT interventional study , consider clinical outcome endpoints traditional sense intervention carry . These consider clinical characteristic phenotype associate genotype polymorphism .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<mesh_term>Dipyridamole</mesh_term>
	<criteria>Subjects without coronary artery disease undergoing Persantine nuclear stress test Oral persantine use within 24 hour Second third degree AV block , sick sinus syndrome without function pacemaker Active asthma bronchospasm Those endstage liver disease cirrhosis active hepatitis &gt; 5 fold liver enzyme elevation include Anemia ( Hct &lt; 30 ) Myocardial infarction within 30 day Severe leave ventricular dysfunction ( EF &lt; 30 % )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>nucleoside</keyword>
	<keyword>neurotransmitter</keyword>
	<keyword>myocardial ischemia</keyword>
	<keyword>Adenosine</keyword>
</DOC>